| Jun 24 |
Alnylam shares soar on positive data from its heart drug study
|
| Jun 24 |
Alnylam Soars After Drug Meets Goal in Heart Disease Trial
|
| Jun 24 |
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
|
| Jun 24 |
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
|
| Jun 24 |
Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?
|
| Jun 24 |
Alnylam claims success in closely watched heart drug study
|
| Jun 19 |
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shift From Loss To Profit
|
| Jun 12 |
Citi opens upside catalyst watch on Alnylam ahead of ATTR-CM data
|
| Jun 7 |
Alnylam, Pliant among stocks yet to face Q2 catalysts: Wells Fargo
|
| Jun 5 |
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
|
